Kesin launches first FDA-approved specialty brand

Specialty Products

Kesin is committed to developing a portfolio of strategic NDA505(b)(2) brand products to increase patient adherence and accessibility. Our technology-driven solutions support increased convenience, effectiveness, and persistence.

alt
kesin caret

LIKMEZTM (metronidazole) Oral Suspension

Our technology-driven solutions support increased convenience, effectiveness, and adherence. The only FDA-approved metronidazole for the treatment of antimicrobial infections that:

  • Addresses the unmet need in patients with dysphagia (difficulty swallowing) or taste aversion

  • Avoids risks associated with drug compounding

  • May help prevent discontinuation-related anti-microbial resistance

 

See full prescribing information for complete BOXED WARNING here.

Product Pipeline*

Product
Name

Therapeutic
Area

Early Stage
Development

Late Stage
Development

Filed for
Approval

FDA
Approved

LIKMEZTM

Anti-Infective

KSN-SP-002

CVS

KSN-SP-003

Migraine

Multiple candidates

*Products pending FDA approval.

Product Pipeline*

Product Name
Therapeutic Area
Stage
LIKMEZTM
Anti-Infective
FDA Approved
KSN-SP-002
CVS
Filed for Approval
KSN-SP-003
Migraine
Late Stage Development
Multiple candidates
Early Stage Development

*Products pending FDA Approval.. The safety or effectiveness of the products has not been established.

Our solutions enhance traditional therapies impacting the adherence obstacles within the patient journey.